彭瑜,张钲,白明,潘晨亮,唐宇宁,蔡玮婷,乔鑫,丁丽琼

• 1:兰州大学第一医院心脏中心

摘要(Abstract)：

目的探讨平均血小板体积(MPV)和血小板聚集率与急性冠状动脉综合征(ACS)患者经皮冠状动脉介入治疗(PCI)术后主要不良心血管事件(MACE)及支架内血栓的相关性。方法连续入选ACS并行PCI患者1425例,根据入院时MPV水平三分位分组:低MPV组(T1组),MPV≤11.0 f L,477例;中MPV组(T2组),MPV 11.0~12.1 f L,448例;高MPV组(T3组),MPV>12.1 f L,500例。通过单因素分析及Cox回归分析确定MACE的预测因素。结果 ACS患者PCI术后12个月累计MACE发生率为4.42%,Cox分析结果显示高MPV值(OR 1.46,95%CI 1.06~2.01)与血小板抵抗(OR 2.31,95%CI 1.40~3.80)是12个月MACE的独立预测因素(P<0.05)。高MPV值与血小板抵抗和支架内血栓的发生显著相关(P<0.05),且两者间存在微弱的正相关。结论 MPV与血小板对ADP反应性是ACS患者PCI术后远期MACE的预测因素,并与支架内血栓的发生相关。

关键词(KeyWords)： 急性冠状动脉综合征;平均血小板体积;血小板功能检测;支架内血栓

Abstract:

Keywords:

基金项目(Foundation): 国家重点临床科室项目(2013);; 甘肃省重点实验室项目(2012);; 甘肃省自然科学基金项目(1308RJZA208)

作者(Author): 彭瑜,张钲,白明,潘晨亮,唐宇宁,蔡玮婷,乔鑫,丁丽琼

参考文献(References)：

• [1]Patel RS,Su S,Neeland IJ,et al.The chromosome 9p21 risk locus is associated with angiographic severity and progression of coronary artery disease.Eur Heart J,2010,31:3017-3023.
• [2]Tantry US,Gurbel PA.Antiplatelet drug resistance and variability in response:the role of antiplatelet therapy monitoring.Curr Pharm Des,2013,19:3795-3815.
• [3]Kamath S,Blann AD,Lip GY.Platelet activation:assessment and quantification.Eur Heart J,2001,22:1561-1571.
• [4]Huczek Z,Kochman J,Filipiak KJ,et al.Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention.J Am Coll Cardiol,2005,46:284-290.
• [5]许文亮,王旭,邵一兵,等.接受直接经皮冠状动脉介入治疗的ST段抬高型急性心肌梗死患者血小板体积的变化及与冠状动脉影像的关系.中国介入心脏病学杂志,2012,4:194-198.
• [6]Goncalves SC,Labinaz M,Le May M,et al.Usefulness of mean platelet volume as a biomarker for long-term outcomes after percutaneous coronary intervention.Am J Cardiol,2011,107:204-209.
• [7]Thygesen K,Alpert JS,Jaffe AS,et al.Third universal definition of myocardial infarction.J Am Coll Cardiol,2012,60:1581-1598.
• [8]2012 Writing Committee Members,Jneid H,Anderson JL,et al.2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction(updating the 2007 guideline and replacing the 2011 focused update):a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.Circulation,2012,126:875-910.
• [9]Angiolillo DJ,Fernandez-Ortiz A,Bernardo E,et al.Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting.Thromb Res,2005,115:101-108.
• [10]Cutlip DE,Windecker S,Mehran R,et al.Clinical end points in coronary stent trials:a case for standardized definitions.Circulation,2007,115:2344-2351.
• [11]Shah B,Sha D,Xie D,et al.The relationship between diabetes,metabolic syndrome,and platelet activity as measured by mean platelet volume:the National Health And Nutrition Examination Survey,1999-2004.Diabetes Care,2012,35:1074-1078.
• [12]Sansanayudh N.Mean platelet volume and coronary artery disease:a systematic review and meta-analysis.Int J Cardiol,2014,175:433-440.
• [13]Choi SW,Choi DH,Kim HW,et al.Clinical outcome prediction from mean platelet volume in patients undergoing percutaneous coronary intervention in Korean cohort:Implications of more simple and useful test than platelet function testing.Platelets,2014.25:322-327.
• [14]Eisen A,Bental T,Assali A,et al.Mean platelet volume as a predictor for long-term outcome after percutaneous coronary intervention.J Thromb Thrombolysis,2013,36:469-474.
• [15]Stone GW,Witzenbichler B,Weisz G,et al.Platelet reactivity and clinical outcomes after coronary artery implantation of drugeluting stents(ADAPT-DES):a prospective multicentre registry study.Lancet,2013,382:614-623.
• [16]Park DW,Ahn JM,Song HG,et al.Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention.Am Heart J,2013,165:34-42.
• [17]Vizioli L,Muscari S,Muscari A.The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases.Int J Clin Pract,2009,63:1509-1515.